These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26704347)

  • 1. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Jiang DK; Wu X; Qian J; Ma XP; Yang J; Li Z; Wang R; Sun L; Liu F; Zhang P; Zhu X; Wu J; Chen K; Conran C; Zheng SL; Lu D; Yu L; Liu Y; Xu J
    Hepatology; 2016 Apr; 63(4):1102-11. PubMed ID: 26704347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon-α therapy: A prospective cohort study in China.
    Qi X; Li F; Zhang Y; Zhu H; Yang F; Li X; Jiang X; Chen L; Huang Y; Zhang J
    J Med Virol; 2022 Sep; 94(9):4449-4458. PubMed ID: 35610746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB; Golge N; Akin MS
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha.
    Chen H; Sun J; Zhou B; Xie Q; Liang X; Fan R; Conran C; Xu J; Ji Y; Zhang X; Sun L; Jia J; Wang G; Hou J; Jiang DK
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):196-204.e8. PubMed ID: 31042581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation in STAT4 is associated with treatment response to pegylated interferon in patients with chronic hepatitis B.
    Limothai U; Chuaypen N; Poovorawan K; Poovorawan Y; Tangkijvanich P
    Asian Pac J Allergy Immunol; 2022 Mar; 40(1):87-93. PubMed ID: 31421662
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Xie DY; Wang SM; Yang JM; Wang LH; Chen HY; Huai C; Shang J; Mao Q; Lei CL; Luo GH; Qian J; Lu DR
    World J Gastroenterol; 2016 Nov; 22(44):9813-9821. PubMed ID: 27956805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients.
    Chen H; Sun J; Zhou B; Peng J; Xie Q; Liang X; Fan R; Conran C; Xu J; Ji Y; Zhang X; Sun L; Jia J; Wang G; Hou J; Jiang DK
    Aliment Pharmacol Ther; 2020 Feb; 51(4):469-478. PubMed ID: 31943297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the relationship between hepatitis B virus genotypes and the effect of polyethylene glycol-interferon-alpha therapy on HBeAg-positive chronic hepatitis B].
    Gao GS; Xu XZ; Hu YR; Yan HD
    Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1009-12. PubMed ID: 24503396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B.
    Limothai U; Chuaypen N; Khlaiphuengsin A; Chittmittraprap S; Poovorawan Y; Tangkijvanich P
    Antivir Ther; 2017; 22(8):681-688. PubMed ID: 28291736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
    Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
    J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single Nucleotide Polymorphism of Interferon Lambda-4 Gene is not Associated with Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B.
    Limothai U; Wasitthankasem R; Poovorawan Y; Tangkijvanich P
    Asian Pac J Cancer Prev; 2015; 16(13):5515-9. PubMed ID: 26225703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of the interactions of STAT4 rs7574865 with HBV mutations on the risk of hepatocellular carcinoma.
    Yang C; Chen H; Zhou B; Yin J; Cao G; Hou J; Jiang D
    Mol Carcinog; 2022 Oct; 61(10):933-940. PubMed ID: 35880842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of interferon-gamma inducible protein 10 polymorphism with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B.
    Limothai U; Chuaypen N; Khlaiphuengsin A; Posuwan N; Wasitthankasem R; Poovorawan Y; Tangkijvanich P
    Antivir Ther; 2016; 21(2):97-106. PubMed ID: 26376789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Short-term efficacy of adefovir dipivoxil as an add-on therapy in the pegylated IFNalpha-2a treatment for HBeAg positive chronic hepatitis B patients].
    Chen LB; Shu X; Jie YS; Yang XA; Zhang K; Li G; Xu QH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Feb; 24(1):39-41. PubMed ID: 20848847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
    Xie Z; Zhou F; Zhou Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):878-81. PubMed ID: 23803202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.